China reorganises regulatory agencies to streamline decisions, cut costs and raise quality
This article was originally published in Clinica
Executive Summary
China is in the midst of a drive to trim its government workforce by half and to consolidate agencies. For the in vitro diagnostics (IVD) industry, this period of upheaval heralds constructive change because it will surely streamline the way these products are regulated, as Karen Riley reports from a conference on international regulatory and reimbursement strategies for IVDs in Chicago.